EXTENDED REPORT

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

D van der Heijde¹, L Klareskog², A Singh³, J Tornero⁴, J Melo-Gomes⁵, C Codreanu⁶, R Pedersen⁷, B Freundlich⁷, S Fatenejad⁸

¹ Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
² Rheumatology Unit, Department of Medicine, Karolinska Institutet/Karolinska University Hospital, Stockholm, Sweden
³ Global Health Outcomes Assessment, Wyeth Research, Collegeville, PA, USA
⁴ Rheumatology, Hospital General de Guadalajara, Guadalajara, Spain
⁵ Rheumatology, SERVIMED, Lisbon, Portugal
⁶ Centrul de Boli Reumatismale, Bucuresti, Romania
⁷ Global Medical Affairs, Wyeth Research, Collegeville, PA, USA
⁸ Clinical Research and Development, Wyeth Research, Collegeville, PA, USA

Correspondence to:
Professor D van der Heijde
Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands; dhe{at}sint.azm.nl

Objective: To compare patient reported measures of function, health related quality of life (QoL), and satisfaction with medication among patients with rheumatoid arthritis (RA) treated with methotrexate (MTX), etanercept, or both for up to 1 year.

Methods: In a 52 week, double blind, clinical trial, patients with active RA were randomised to receive etanercept 25 mg twice weekly, methotrexate up to 20 mg weekly, or combination therapy. The Health Assessment Questionnaire (HAQ) disability index, EuroQoL health status visual analogue scale (EQ-5D VAS), patient global assessment, and patient general health VAS were administered at baseline and weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52. Satisfaction with the medication was compared at 52 weeks.

Results: Of 682 enrolled patients, 522 completed 52 weeks of treatment. Mean improvement from baseline in HAQ score was 0.65, 0.70, and 1.0 for MTX, etanercept, and the combination, respectively. The mean percentage and absolute improvement in the HAQ was significantly higher (p<0.01) for combination therapy than for either of the monotherapies. Combination therapy produced significantly more rapid achievement of HAQ 0.5 sustained for 6 months than either of the monotherapies (p<0.01). Compared with patients receiving monotherapy, those receiving combination therapy achieved a significantly better (p<0.05) health state as measured by the EQ-5D VAS (mean (SD) 63.7 (3.2), 66.8 (3.2), 72.7 (3.1) for MTX, etanercept, and the combination, respectively). Results were similar for other assessments (p<0.01). Patients in combination and etanercept groups were significantly more likely (p<0.0001, p = 0.0009, respectively) to report satisfaction with the medication.

Conclusions: Combination therapy with etanercept and methotrexate improved function, QoL, and satisfaction with the medication significantly more than monotherapy.

Keywords: rheumatoid arthritis; etanercept; methotrexate; functional status; disability; patient outcome assessment; quality of life

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Karonitsch, T, Aletaha, D, Boers, M, Bombardieri, S, Combe, B, Dougados, M, Emery, P, Felson, D, Gomez-Reino, J, Keystone, E, Kvien, T K, Martin-Mola, E, Matucci-Cerinic, M, Richards, P, van Riel, P, Siegel, J, Smolen, J S, Sokka, T, van der Heijde, D, van Vollenhoven, R, Ward, M, Wells, G, Zink, A, Landewe, R (2008). Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. Ann Rheum Dis 67: 1365-1373 [Abstract] [Full Text]  
• van der Heijde, D, Landewe, R, van Vollenhoven, R, Fatenejad, S, Klareskog, L (2008). Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 67: 1267-1270 [Abstract] [Full Text]  
• van Riel, P L C M, Freundlich, B, MacPeek, D, Pedersen, R, Foehl, J R, Singh, A, on behalf of ADORE study investigators, (2008). Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 67: 1104-1110 [Abstract] [Full Text]  
• Donahue, K. E., Gartlehner, G., Jonas, D. E., Lux, L. J., Thieda, P., Jonas, B. L., Hansen, R. A., Morgan, L. C., Lohr, K. N. (2008). Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis. ANN INTERN MED 148: 124-134 [Abstract] [Full Text]  
• Heiberg, M S, Rodevand, E, Mikkelsen, K, Kaufmann, C, Didriksen, A, Mowinckel, P, Kvien, T K (2006). Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study. Ann Rheum Dis 65: 1379-1383 [Abstract] [Full Text]  
• Howe, C. R., Gardner, G. C., Kadel, N. J. (2006). Perioperative medication management for the patient with rheumatoid arthritis.. J Am Acad Orthop Surg 14: 544-551 [Abstract] [Full Text]